Cancer Letters

Cancer Letters

Volume 156, Issue 1, 1 August 2000, Pages 27-35
Cancer Letters

Peroxiredoxin I expression in oral cancer: a potential new tumor marker

https://doi.org/10.1016/S0304-3835(00)00434-1Get rights and content

Abstract

This study investigates the applicability of the novel antioxidant protein, peroxiredoxin (Prx) I as a marker for tumor status in oral squamous cell carcinoma (SCC). Samples from 53 patients with SCC in the oral cavity were examined by immunohistochemistry. Correlations between the expression level of Prx I and proliferating cell nuclear antigen (PCNA), the clinical features of tumors, and their histopathological classifications were statistically analyzed. Cases exhibiting low Prx I expression level included significantly more with larger tumor mass cases (T-category, P=0.004), positive lymph node metastasis (N-category, P=0.015), advanced stage (P=0.002), and poorly differentiated cells (P=0.020). There was no significant difference between Prx I expression and the other indices.

Introduction

The degree of cell proliferation in malignant tumors contributes to the understanding of predictive factors among patients with these neoplasms. There are many reports of markers for proliferation, argynophilic nucleolar organizer regions (AgNORs), Ki67 and proliferating cell nuclear antigen (PCNA) [1], [2], [3], [4], [5].

Recently, the proliferation associated gene (pag) was isolated from a ras-transformed human mammary epithelial cell line. This gene is constitutively expressed in human tissues and more highly expressed during proliferation [6]. The product of pag (Pag) is later classified into the peroxiredoxin (Prx) I family and is a physiological inhibitor of c-Abl tyrosine kinase activity [7]. Prx is an antioxidant protein family found in a wide variety of species [8], [9], [10], [11]. Yeast and mammalian Prx proteins have thioredoxin peroxidase (TPx) activity and reduce hydrogen peroxide [12]. The mammalian Prx group is divided into three subfamilies: Prx I, Prx II, and Prx III [13]. Prx I is well known as an oxidative stress-inducible protein. Proteins in this family include MSP23 in murine macrophages, natural killer enhancing factor (NKEF) in red blood cells (RBC) and Pag in human cells. MSP23 was cloned from murine peritoneal macrophages as an oxidative stress inducible protein, and its transcription level also increases in response to oxidative stress [9]. NKEF, which was identified in RBC cytosol and mediates an enhancement in natural killer activity, is induced by H2O2 [14]. Prx I participates in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentration of H2O2 [12]. These facts suggest that Prx I activity may be associated with, not only proliferation, but also with formation of reactive oxygen species (ROS). ROS are produced by inflammatory cell infiltration and indicate that cellular response. Furthermore the relation between cancer and some ant-oxidatants, such as thiroedoxins and glutathion peroxidase, is presented [15], [16], [17], [18], [19].

Although the importance of Prx I in cancer is suggested by its association with proliferation, oncogene products and oxidative stress, there have been no studies investigating the possibility of using Prx I expression as a marker for clinical tumor status. Towards this goal, we have examined correlation between Prx I expression and the clinical status of squamous cell carcinoma in the oral cavity, using immunohistochemistry and histological classification.

Section snippets

Patients

The specimens were obtained by surgical biopsy from the oral cavities from 53 Japanese patients with squamous cell carcinoma, who were referred to the Department of Oral and Maxillofacial Surgery at Tsukuba University Hospital from 1993 to 1997. The clinical features of these patients are summarized in Table 1. No patients received treatment for the malignant tumor prior to biopsy. The TNM categories were determined by clinical findings, radiographs, and CT scans. Staging of the tumors was

Immunohistological analysis of Prx I expression

Prx I expression was observed in 83% of the specimens examined, especially in the epithelium of the SCC (Fig. 2A). Prx I expression was also observed in the stratum basale of normal epidermis. Because both Prx I and PCNA immunostaining spots were assumed to correspond to proliferating cells, the locations of Prx I and PCNA were compared. Serial slices of one sample were stained by Prx I and PCNA antibodies individually, and the localization of the two different antigens were examined. We also

Discussion

The pag gene expression has been reported to increase in cells entering the S-phase [25]. Immunohistochemical localization revealed that PCNA increases in late G1, peaks in S, decreased through G2, and is undetectable in M-phase and quiescent cells [26]. Although the expression period in the cell cycle is considered to be same from these reports, the immunohistochemical distribution of each antigen is different. In this study, marked PCNA expression was observed in the nuclei of basal layer

Acknowledgements

This work is supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports, and Culture in Japan. We thank Dr Shimokama for pathological advice.

References (37)

  • A.K El-Naggar et al.

    Expression of p16 Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical

    Hum. Pathol.

    (1999)
  • P Pande et al.

    pRb and p16 protein alterations in human oral tumorigenesis

    Oral Oncol.

    (1998)
  • Z.P Pavelic et al.

    Absence of retinoblastoma gene product in human primary oral cavity carcinomas

    Oral Oncol.

    (1996)
  • S Aaltomaa et al.

    Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining

    Anticancer Res.

    (1992)
  • I.F al Sheneber et al.

    Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer

    Cancer

    (1993)
  • M Derenzini et al.

    AgNOR proteins as a parameter of the rapidity of cell proliferation

    Zentralbl Pathol.

    (1994)
  • F Hofstadter et al.

    Cell proliferation assessment in oncology

    Virchows Arch.

    (1995)
  • J.M Elias

    Cell proliferation indexes: a biomarker in solid tumors

    Biotech.-Histochem.

    (1997)
  • Cited by (104)

    • Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance

      2017, DNA Repair
      Citation Excerpt :

      Peroxiredoxins are broadly distributed thiol-specific antioxidants with peroxidase activity that are divided into six groups (Prx1-6). Prx1 overexpression has been reported in a number of human cancers including breast, lung, oral, and thyroid [148–151]. Kim et al. showed that Nrf2 and Prx1 mRNA levels are significantly increased in tumor samples from patients with non-small cell lung cancer, and overexpression of Prx1 has strong association with disease recurrence and shorter overall survival in these patients [152].

    View all citing articles on Scopus
    View full text